1717 K Street NW, Suite 900

Washington, DC 20006-5349

(877) 363-6376

HELPLINE

NEWS

Upcoming MTME discussing the tumor treating fields device for mesothelioma with Dr. Zachary Horne

Tumor Treating Fields

Join us next Tuesday, June 9 at 2:00 PM ET for a Meet the Mesothelioma Experts (MTME) interview with Dr. Zachary Horne on Facebook Live.

This discussion will cover the Optune Lua tumor treating fields device by Novocure, including the science behind the device and some practical and logistical questions about it. 

Unlike our previous MTME installments, this one does not require registration. You can access the video at facebook.com/curemeso/live/ or by clicking the button below. No Facebook account needed.

This event is made possible by an educational grant by Novocure.

About the Speaker:

Zachary Horne, MD, is a radiation oncologist at the Allegheny Health Network Cancer Institute Division of Radiation Oncology in Pittsburgh, PA. Dr. Horne received his medical degree from the George Washington University School of Medicine and completed his residency at the University of Pittsburgh Medical Center. He is board certified by the American Board of Radiology.

As part of the Meet the Mesothelioma Experts series, the Meso Foundation invites specialists in the field of mesothelioma to discuss their current research interests as well as promising developments in the treatment of mesothelioma. You can listen to audio files of past sessions on our website. If you wish to receive emails from the Meso Foundation, including alerts about new installments of the Meet the Mesothelioma Experts series, please sign up for our news on the right side of your screen.

Also...

In Other News

Clinical Trials

Mesothelioma is one of the rarest cancers so there are always clinical trials going on to advance research efforts. This session presents on four different

Read More »

Peritoneal Surgery/HIPEC

Peritoneal mesothelioma patients have a few different treatment options available. This session discusses two options: surgery as well as hyperthermic intraperitoneal chemotherapy (HIPEC).  This session

Read More »

Share:

Facebook
Twitter
LinkedIn